- Home
- ZBAI vs ADVB Comparison
ZBAI vs ADVB Comparison
Compare ZBAI & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBAI
- ADVB
- Stock Information
- Founded
- ZBAI 2015
- ADVB 2014
- Country
- ZBAI United States
- ADVB United States
- Employees
- ZBAI N/A
- ADVB N/A
- Industry
- ZBAI Professional Services
- ADVB Medical Specialities
- Sector
- ZBAI Consumer Discretionary
- ADVB Health Care
- Exchange
- ZBAI Nasdaq
- ADVB Nasdaq
- Market Cap
- ZBAI 11.3M
- ADVB 12.2M
- IPO Year
- ZBAI N/A
- ADVB 2025
- Fundamental
- Price
- ZBAI $8.62
- ADVB $0.46
- Analyst Decision
- ZBAI
- ADVB
- Analyst Count
- ZBAI 0
- ADVB 0
- Target Price
- ZBAI N/A
- ADVB N/A
- AVG Volume (30 Days)
- ZBAI 90.7K
- ADVB 947.6K
- Earning Date
- ZBAI 12-18-2025
- ADVB 10-27-2025
- Dividend Yield
- ZBAI N/A
- ADVB N/A
- EPS Growth
- ZBAI N/A
- ADVB N/A
- EPS
- ZBAI N/A
- ADVB N/A
- Revenue
- ZBAI $720,000.00
- ADVB N/A
- Revenue This Year
- ZBAI N/A
- ADVB N/A
- Revenue Next Year
- ZBAI N/A
- ADVB N/A
- P/E Ratio
- ZBAI N/A
- ADVB N/A
- Revenue Growth
- ZBAI 44.00
- ADVB N/A
- 52 Week Low
- ZBAI $4.83
- ADVB $0.34
- 52 Week High
- ZBAI $45.00
- ADVB $4.10
- Technical
- Relative Strength Index (RSI)
- ZBAI 51.71
- ADVB 49.73
- Support Level
- ZBAI $7.98
- ADVB $0.43
- Resistance Level
- ZBAI $8.96
- ADVB $0.62
- Average True Range (ATR)
- ZBAI 0.73
- ADVB 0.06
- MACD
- ZBAI -0.14
- ADVB 0.00
- Stochastic Oscillator
- ZBAI 32.34
- ADVB 28.36
About ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.